STAT3 is known to be activated in both ALK-positive and ALK-negative ALCLs18, and we found that the administration with a STAT3 inhibitor Stattics declined the SLAMF8 expression protein levels in the ALK-positive ALCL cell lines (data not shown). This evidence concerns the gene SLAMF8 and anaplastic large cell lymphoma.